

Thomas D Gossios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/603472/publications.pdf>

Version: 2024-02-01

46
papers

1,539
citations

430874

18
h-index

315739

38
g-index

46
all docs

46
docs citations

46
times ranked

2503
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. <i>Hellenic Journal of Cardiology</i> , 2022, 63, 15-21.	1.0	11
2	Deciphering hypertrophic cardiomyopathy with electrocardiography. <i>Heart Failure Reviews</i> , 2022, 27, 1313-1323.	3.9	3
3	An overview of heart rhythm disorders and management in myotonic dystrophy type 1. <i>Heart Rhythm</i> , 2022, 19, 497-504.	0.7	2
4	Smoking in childhood and early adolescence: A case of the early bird not catching the worm. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e1-e2.	1.8	0
5	The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2021, 37, 857-866.	1.7	28
6	A simple algorithm for a clinical step-by-step approach in the management of hypertrophic cardiomyopathy. <i>Future Cardiology</i> , 2021, 17, 1395-1405.	1.2	0
7	Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy. <i>Current Pharmaceutical Design</i> , 2021, 27, 1254-1265.	1.9	1
8	A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1038-1048.	3.2	8
9	Pathogenesis, Diagnosis and Risk Stratification in Arrhythmogenic Cardiomyopathy. <i>Neurology International</i> , 2021, 11, 263-289.	0.5	0
10	Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 326-336.	1.2	90
11	Right arm distal transradial (snuffbox) access for coronary catheterization: Initial experience. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 106-109.	1.0	39
12	“Thunderball”: Oscillating ball thrombus within a giant sinus of Valsalva aneurysm. <i>Hellenic Journal of Cardiology</i> , 2020, 62, 241-243.	1.0	0
13	“Take my breath away”™: arrhythmogenic tricuspid annulus lipomatous infiltration. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-2.	0.6	0
14	Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1686-1694.	2.3	6
15	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. <i>Circulation</i> , 2019, 140, 293-302.	1.6	131
16	Multimodal Treatment of Homozygous Familial Hypercholesterolemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 3616-3621.	1.9	5
17	Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 331-339.	1.0	33
18	Acute Coronary Syndrome in Patients With Inflammatory Bowel Diseases: The Plaque and the Thrombus. <i>Angiology</i> , 2017, 68, 843-844.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2206-2212.	1.9	9
20	The Potential of Late Gadolinium Enhancement to Serve as a Predictor of Ventricular Arrhythmias in Hypertrophic Cardio-myopathy Patients. <i>Open Hypertension Journal</i> , 2016, 8, 1-11.	0.8	0
21	Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. <i>Current Vascular Pharmacology</i> , 2015, 13, 368-380.	1.7	11
22	Renal Denervation. <i>Angiology</i> , 2014, 65, 760-768.	1.8	3
23	Is There an Association Between Inflammatory Bowel Diseases and Carotid Intima-media Thickness? Preliminary Data. <i>Angiology</i> , 2014, 65, 543-550.	1.8	30
24	Carotid Intima-Media Thickness in Patients With Inflammatory Bowel Disease. <i>Angiology</i> , 2014, 65, 284-293.	1.8	25
25	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 936-944.	1.3	20
26	Are Patients With Inflammatory Bowel Diseases at Increased Risk for Cardiovascular Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2134-2135.	4.4	6
27	Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. <i>World Journal of Cardiology</i> , 2014, 6, 26.	1.5	35
28	Hypertrophic cardiomyopathy associated with an anomalous origin of right coronary artery. <i>Herz</i> , 2013, 38, 427-430.	1.1	5
29	Left ventricular hypertrophy caused by a novel nonsense mutation in FHL1. <i>European Journal of Medical Genetics</i> , 2013, 56, 251-255.	1.3	22
30	Clinical Characteristics and Natural History of Hypertrophic Cardiomyopathy With Midventricular Obstruction. <i>Circulation Journal</i> , 2013, 77, 2366-2374.	1.6	76
31	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.9	40
32	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	1.7	19
33	Role of Antihypertensive Drugs in Arterial "De-Stiffening"™ and Central Pulsatile Hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 143-156.	2.2	49
34	Editorial The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , 2012, 1, 6-10.	0.9	3
35	Raised liver enzymes in patients taking statins " Authors' reply. <i>Lancet</i> , The, 2011, 377, 1075-1076.	13.7	1
36	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , 2011, 6, 1067-1075.	0.9	9

#	ARTICLE	IF	CITATIONS
37	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Archives of Medical Science, 2011, 6, 984-992.	0.9	46
38	Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management. Current Vascular Pharmacology, 2011, 9, 465-470.	1.7	1
39	Prognostic value of right ventricular diastolic function indices in hypertrophic cardiomyopathy. European Journal of Echocardiography, 2011, 12, 809-817.	2.3	33
40	Residual cardiac risk reduction beyond lipid lowering. Hellenic Journal of Cardiology, 2011, 52, 197-203.	1.0	1
41	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. Current Vascular Pharmacology, 2010, 8, 792-803.	1.7	13
42	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet, The, 2010, 376, 1916-1922.	13.7	594
43	Effect of antihypertensive drug-associated diabetes on cardiovascular risk. Hellenic Journal of Cardiology, 2010, 51, 195-9.	1.0	3
44	Atherosclerotic Renal Artery Stenosis: Medical Therapy Alone or in Combination with Revascularization?. Angiology, 2009, 60, 397-402.	1.8	5
45	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. Circulation Journal, 2007, 71, 1120-1127.	1.6	119
46	Mitral regurgitation impact on left atrial myopathy in hypertrophic cardiomyopathy. Echocardiography, 0, , .	0.9	1